

ASX Announcement

BCAL Diagnostics Launch of BREASTEST *plus*™ Investor Webinar

Sydney, Australia – 31 March 2025 – BCAL Diagnostics Limited (ASX: BDX) wishes to advise that it will host an analyst and investor webinar to discuss the launch of BREASTEST *plus*™ on Wednesday 2 April at 12:00pm AEDT.

BCAL Diagnostics CEO, Shane Ryan will be joined by Dr David Speakman, Specialist Breast Surgeon and Head of BCAL's Clinical Advisory Board.

Webinar Registration

Please use the following link to register for the webinar:

Webinar Registration Link:

<https://s1.c-conf.com/diamondpass/10046419-pk3wc6.html>

This announcement has been approved for release by the Executive Chair of BCAL Diagnostics Limited.

ENDS

For further information:

Jayne Shaw
Executive Chair
Jshaw@bcaldiagnostics.com

Shane Ryan
Chief Executive Officer
Sryan@bcaldiagnostics.com

Investor & Media Enquiries
Tanya Thomas
Director Investor Relations &
Communications
Tthomas@bcaldiagnostics.com

About BREASTEST *plus*™

BREASTEST *plus*™ is the first product in BCAL's BREASTEST® range of non-invasive, lipid-based breast cancer diagnostics. BREASTEST *plus*™ is a first in class blood test that measures a panel of lipids, using Liquid Chromatography Mass Spectrometry, to identify a lipidomic breast cancer signature. BREASTEST *plus*™ is a 'rule-out' test that has been designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

About BCAL Diagnostics

BCAL Diagnostics is an Australian and US-based biotechnology company dedicated to advancing early and accurate breast cancer detection. Our innovative, non-invasive blood test, the first in the BREASTEST® range of products is designed to complement existing breast screening methods and provide additional lipidomic insights to rule-out breast cancer, empowering women and their clinicians with greater confidence in diagnostic outcomes. Improved screening accuracy potentially reduces unnecessary follow-ups and enables timely intervention resulting in better health outcomes for women.

Founded in 2010, BCAL is headquartered in Sydney, AUS and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.